Activated immune system and inflammation in healthy ageing: Relevance for tryptophan and neopterin metabolism

Current Pharmaceutical Design

Volumn 20, Issue 38, 2014, Pages 6048-6057

  Capuron, Lucile ^a   Geisler, Simon ^b   Kurz, Katharina ^c   Leblhuber, Friedrich ^d   Sperner Unterweger, Barbara ^b   Fuchs, Dietmar ^b  

^a NutriNeuro Bordeaux University   (France)

^b INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^c INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^d KEPLER UNIVERSITY HOSPITAL   (Austria)

Author keywords

Aging; Antioxidants; Inflammation; Neopterin; Tryptophan breakdown; Vitamins

Indexed keywords

ALPHA TOCOPHEROL; ASCORBIC ACID; CYANOCOBALAMIN; FOLIC ACID; GAMMA INTERFERON; HOMOCYSTEINE; INDOLEAMINE 2,3 DIOXYGENASE; KYNURENINE; NEOPTERIN; PHENYLALANINE; PYRIDOXINE; REACTIVE OXYGEN METABOLITE; TRYPTOPHAN; VITAMIN D;

AGED; AGING; AMINO ACID ANALYSIS; AMINO ACID METABOLISM; ANEMIA; ARTICLE; AUTOIMMUNE DISEASE; CACHEXIA; CARDIOVASCULAR MORTALITY; COGNITIVE DEFECT; CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; DISEASE COURSE; ENZYME ACTIVITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYPERHOMOCYSTEINEMIA; IMMUNE DEFICIENCY; IMMUNE SYSTEM; IMMUNOBIOLOGY; IMMUNOREACTIVITY; INFECTION; INFLAMMATION; MOOD DISORDER; NEOPLASM; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; STIMULATION; TH1 CELL; VITAMIN DEFICIENCY; WEIGHT REDUCTION; ANIMAL; CELLULAR IMMUNITY; HEALTH STATUS; IMMUNOLOGY; METABOLISM; PHYSIOLOGY;

AGING; ANIMALS; HEALTH STATUS; HUMANS; IMMUNITY, CELLULAR; INFLAMMATION; NEOPTERIN; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES; TRYPTOPHAN;

EID: 84922971289     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612820666140317110217     Document Type: Article

References (136)

1. Wick G, Grubeck-Loebenstein B. Primary and secondary alterations of immune reactivity in the elderly: impact of dietary factors and disease. Immunol Rev 1997; 160: 171-84.
2. Knight JA. The biochemistry of aging. Adv Clin Chem 2000; 35: 1-62.
3. Reibnegger G, Huber LA, Jürgens G, et al. Approach to define "normal aging" in man. Immune function, serum lipids, lipoproteins and neopterin levels. Mech Ageing Dev 1988; 46: 67-82.
4. Diamondstone LS, Tollerud DJ, Fuchs D, et al. Factors influencing serum neopterin and beta 2-microglobulin levels in a healthy diverse population. J Clin Immunol 1994; 14: 368-4.
5. Fahey JL, Schnelle JF, Boscardin J, et al. Distinct categories of immunologic changes in frail elderly. Mech Ageing Dev 2000; 115: 1-20.
6. Spencer ME, Jain A, Matteini A, et al. Serum levels of the immune activation marker neopterin change with age and gender and are modified by race, BMI, and percentage of body fat. J Gerontol A Biol Sci Med Sci 2010; 65: 858-65.
7. Catania A, Airaghi L, Motta P, et al. Cytokine antagonists in aged subjects and their relation with cellular immunity. J Gerontol A Biol Sci Med Sci 1997; 52: B93-7.
8. Solichova D, Melichar B, Blaha V, et al. Biochemical profile and survival in nonagenarians. Clin Biochem 2001; 134: 563-9.
9. Spencer ME, Jain A, Matteini A, et al. Serum levels of the immune activation marker neopterin change with age and gender and are modified by race, BMI, and percentage of body fat. J Gerontol A Biol Sci Med Sci 2010; 65: 858-65.
10. Frick B, Schroecksnadel K, Neurauter G, Leblhuber F, Fuchs D. Increasing production of homocysteine and neopterin and degradation of tryptophan with older age. Clin Biochem 2004; 37: 684-7.
11. Pertovaara M, Raitala A, Lehtimäki T, et al. Indoleamine 2,3-dioxygenase activity in nonagenarians is markedly increased and predicts mortality. Mech Ageing Dev 2006; 127: 497-9.
12. Harrison DE, Strong R, Sharp ZD, et al. Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature 2009; 460: 392-5.
13. Kaeberlein M. Resveratrol and rapamycin: are they anti-aging drugs? BioEssays 2010; 32: 96-9.
14. Wirleitner B, Schroecksnadel K, Winkler C, Schennach H, Fuchs D. Resveratrol suppresses interferon-gamma-induced biochemical pathways in human peripheral blood mononuclear cells in vitro. Immunol Lett 2005; 100: 159-63.
15. Schroecksnadel S, Sucher R, Kurz K, Fuchs, Brandacher G. Influence of immunosuppressive agents on tryptophan degradation and neopterin production in human peripheral blood mononuclear cells. Transplant Immunol 2011; 25: 119-23.
16. Huber C, Batchelor JR, Fuchs D, et al. Immune responseassociated production of neopterin-Release from macrophages primarily under control of interferon-gamma. J Exp Med 1984; 160: 310-6.
17. Wirleitner B, Reider D, Ebner S, et al. Monocyte-derived dendritic cells release neopterin. J Leukocyte Biol 2002; 72: 1148-53.
18. Fuchs D, Weiss G, Reibegger G, Wachter H. The role of neopterin as a monitor of cellular immune activation in transplantation, inflammatory, infectious and malignant diseases. Crit Rev Clin Lab Sci 1992; 29: 307-41.
19. Widner B, Baier-Bitterlich G, Wede I, Wirleitner B, Wachter H, Fuchs D. Neopterin: indicator of oxidative stress and part of the cytotoxic armature of activated macrophages in humans. Pteridines 1998; 9: 91-102.
20. Murr C, Widner B, Wirleitner B, Fuchs D. Neopterin as a marker for immune system activation. Current Drug Metabolism 2002; 3: 175-87.
21. Werner ER, Blau N, Thöny B. Tetrahydrobiopterin: biochemistry and pathophysiology. Biochem J 2011; 438: 397-414.
22. Watschinger K, Keller MA, Golderer G, et al. Identification of the gene encoding alkylglycerol monooxygenase defines a third class of tetrahydrobiopterin-dependent enzymes. Proc Natl Acad Sci USA 2010; 107: 13672-77.
23. Kwon NS, Nathan CF, Stuehr DJ. Reduced biopterin as a cofactor in the generation of nitrogen oxides by murine macrophages. J Biol Chem 1989; 264: 20496-501.
24. Werner ER, Werner-Felmayer G, Fuchs D, Hausen A, Reibnegger G, Wachter H. Parallel induction of tetrahydrobiopterin biosynthesis and indoleamine 2,3-dioxygenase activity in human cells and cell lines by interferon-gamma. Biochem J 1989; 262: 861-6.
25. Werner ER, Bitterlich G, Fuchs D, et al. Human macrophages degrade tryptophan upon induction by interferon-gamma. Life Sci 1987; 41: 273-80.
26. Carlin JM, Ozaki Y, Byrne GI, Brown RR, Borden EC. Interferons and indoleamine 2,3-dioxygenase: role in antimicrobial and antitumor effects. Experientia 1989; 45: 535-41.
27. Brown RR, Ozaki Y, Datta SP, Borden EC, Sondel PM, Malone DG. Implications of interferon-induced tryptophan catabolism in cancer, auto-immune diseases and AIDS. Adv Exp Med Biol 1991; 294: 425-35.
28. Taylor MW, Feng, GS. Relationship between interferon-[, indoleamine 2,3-dioxygenase, and tryptophan catabolism. FASEB J 1991; 5: 2516-22.
29. Schroecksnadel K, Wirleitner B, Winkler C, Fuchs D. Monitoring tryptophan metabolism in chronic immune activation. Clin Chim Acta 2006; 364: 82-90.
30. Fuchs D, Möller AA, Reibnegger G, Stöckle E, Werner ER, Wachter H. Decreased serum tryptophan in patients with HIV-1 infection correlates with increased serum neopterin and with neurologic/psychiatric symptoms. J Acquir Immune Defic Syndr 1990; 3: 873-6.
31. Kurz K, Schroecksnadel S, Weiss G, Fuchs D. Association between increased tryptophan degradation and depression in cancer patients. Curr Opin Clin Nutr Metabol Care 2011; 14: 49-56.
32. Heyes MP, Saito K, Markey SP. Human macrophages convert Ltryptophan into the neurotoxin quinolinic acid. Biochem J 1992; 283: 633-5.
33. Heyes MP, Saito K, Crowley JS, et al. Quinolinic acid and kynurenine pathway metabolism in inflammatory and noninflammatory neurological disease. Brain 1992;115: 1249-73.
34. Stone TW. Neuropharmacology of quinolinic and kynurenic acids. Pharmacol Rev 1993; 45: 309-79.
35. Weinlich G, Murr C, Richardsen L, Winkler C, Fuchs D. Decreased serum tryptophan concentration predicts poor prognosis in malignant melanoma patients. Dermatology 2007; 214: 8-14.
36. Werner-Felmayer G, Werner ER, Fuchs D, Hausen A, Reibnegger G, Wachter H. Neopterin formation and tryptophan degradation by a human myelomonocytic cell line (THP-1). Cancer Res 1990; 50: 2863-7.
37. Chen Y, Guillemin GJ. Kynurenine pathway metabolites in humans: disease and healthy states. Int J Tryptophan Res 2009; 2: 1-19.
38. Widner B, Werner ER, Schennach H, Wachter H, Fuchs D. Simultaneous measurement of serum tryptophan and kynurenine by HPLC. Clin Chem 1997; 43: 2424-6.
39. Pedersen ER, Midttun Ø, Ueland PM, et al. Systemic markers of interferon-α-mediated immune activation and long-term prognosis in patients with stable coronary artery disease. Arterioscler Thromb Vasc Biol 2011; 31: 698-704.
40. Thomas SR, Terentis AC, Cai H, et al. Post-translational regulation of human indoleamine 2,3-dioxygenase activity by nitric oxide. J Biol Chem 2007; 282: 23778-87.
41. Shintaku, H. Disorders of tetrahydrobiopterin metabolism and their treatment. Curr Drug Metab 2002; 3: 123-31.
42. Neurauter G, Schröcksnadel K, Scholl-Bürgi S, et al. Chronic immune stimulation correlates with reduced phenylalanine turnover. Curr Drug Metabol 2008; 9: 622-7.
43. Roth E, Zöch G, Schulz F, et al. Amino acid concentrations in plasma and skeletal muscle of patients with acute hemorrhagic necrotizing pancreatitis. Clin Chem 1985; 31: 1305-9.
44. Rath T, Roth E, Keidl R, Meissl G. Phenylalanine: total amino acid ratio in 45 burn patients. Scand J Plast Reconstr Surg Hand Surg 1987; 21: 297-300.
45. Ollenschläger G, Jansen S, Schindler J, Rasokat H, Schrappe-Bächer M, Roth E. Plasma amino acid pattern of patients with HIV infection. Clin Chem 1988; 34: 1787-9.
46. Ploder M, Neurauter G, Spittler A, Schroecksnadel K, Roth E, Fuchs D. Serum phenylalanine in patients post trauma and with sepsis correlate to neopterin concentrations. Amino Acids 2008; 35: 303-7.
47. Neurauter G, Grahmann AV, Klieber M, et al. Serum phenylalanine concentrations in patients with ovarian carcinoma correlate with concentrations of immune activation markers and of isoprostane-8. Cancer Lett 2008; 272: 141-7.
48. Zangerle R, Kurz K, Neurauter G, Kitchen M, Sarcletti M, Fuchs D. Increased blood phenylalanine to tyrosine ratio in HIV-1 infection and correction following effective antiretroviral therapy. Brain Behav Immun 2010; 24: 403-8.
49. Van Gool AR, Fekkes D, Kruit WH, et al. Serum amino acids, biopterin and neopterin during long-term immunotherapy with interferon-alpha in high-risk melanoma patients. Psychiatry Res 2003; 15: 125-32.
50. Zoller H, Schloegl A, Schroecksnadel S, Vogel W, Fuchs D. Influence of interferon-ootherapy on phenylalanine hydroxylase activity in patients with HCV infection. J Interferon Cytokine Res 2012; 32: 216-20.
51. Felger JC, Li L, Marvar PJ, et al. Tyrosine metabolism during interferon-alpha administration: Association with fatigue and CSF dopamine concentrations. Brain Behav Immun 2013; 31: 153-60.
52. Capuron L, Schroecksnadel S, Féart C, et al. Chronic low grade immune activation in the elderly is associated with increased tryptophan catabolism and altered phenylalanine turnover: role in neuropsychiatric symptomatology. Biol Psych 2011; 70: 175-82.
53. Haroon E, Raison CL, Miller AH. Psychoneuroimmunology meets neuropsychopharmacology: translational implications of the impact of inflammation on behavior. Neuropsychopharmacology 2012; 37: 137-62.
54. Selhub J, Jacques PF, Rosenberg IH, et al. Serum total homocysteine concentrations in the third National Health and Nutrition Examination Survey (1991-1994): population reference ranges and contribution of vitamin status to high serum concentrations. Ann Intern Med 1999; 131: 331-9.
55. Herrmann W, Herrmann M, Obeid R. Hyperhomocysteinaemia: a critical review of old and new aspects. Curr Drug Metab 2007; 8: 17-31.
56. Boushey CJ, Beresford SA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. J Am Med Aassoc 1995; 274: 1049-57.
57. McCully KS. Homocysteine and vascular disease. Nat Med 1996; 2: 386-9.
58. Verhoef P, Kok FJ, Kruyssen DA, et al. Plasma total homocysteine, B vitamins, and risk of coronary atherosclerosis. Arterioscler Thromb Vasc Biol 1997; 17: 989-95.
59. Widner B, Fuchs D, Leblhuber F, Sperner-Unterweger B. Does disturbed homocysteine and folate metabolism in depression result from enhanced oxidative stress? J Neurol Neurosurg Psychiatry 2001; 70: 419.
60. Fuchs D, Jaeger M, Widner B, Wirleitner B, Artner-Dworzak E, Leblhuber F. Is hyperhomocysteinaemia due to oxidative depletion of folate rather than to insufficient dietary intake? Clin Chem Med 2001; 39: 691-4.
61. Widner B, Enzinger C, Laich A, Wirleitner B, Fuchs D. Hyperhomocysteinemia, pteridines and oxidative stress. Curr Drug Metab 2002; 3: 225-32.
62. Rudzite V, Jurika E, Jäger M, Fuchs D. Impairment of lipid metabolism due to deficiency of pyridoxal-5-phosphate and/or activated immune system: its interpretation. Pteridines 2000; 11: 107-20.
63. Schröcksnadel K, Frick B, Wirleitner B, Schennach H, Fuchs D. Homocysteine accumulates in supernatants of stimulated human peripheral blood mononuclear cells. Clin Exp Immunol 2003; 134: 53-56.
64. Ploder M, Schroecksnadel K, Spittler A, Neurauter G, Roth E, Fuchs D. Moderate hyperhomocysteinemia in patients with multiple trauma and with sepsis predicts poor survival. Mol Med 2010; 16: 498-504.
65. Nathan CF, Murray HW, Wiebe ME, Rubin BY. Identification of interferon-gamma as the lymphokine that activates human macrophage oxidative metabolism and antimicrobial activity. J Exp Med 1983; 158: 670-89.
66. Mason JB, Miller JW. The effects of vitamins B12, B6, and folate on blood homocysteine levels. Ann N-Y Acad Sci 1992; 30: 197-204.
67. Bønaa KH, Njølstad I, Ueland PM, et al. NORVIT Trial Investigators. Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med 2006; 354: 1578-88.
68. Lee BJ, Huang MC, Chung LJ, et al. Folic acid and vitamin B12 are more effective than vitamin B6 in lowering fasting plasma homocysteine concentration in patients with coronary artery disease. Eur J Clin Nutr 2004; 58: 481-7.
69. Frick B, Gruber B, Schroecksnadel K, Leblhuber F, Fuchs D. Homocysteine but not neopterin declines in demented patients on B vitamins. J Neural Transm 2006; 113: 1815-9.
70. Bleie Ø, Semb AG, Grundt H, et al. Homocysteine-lowering therapy does not affect inflammatory markers of atherosclerosis in patients with stable coronary artery disease. J Intern Med 2007; 262: 244-53.
71. Robinson K, Arheart K, Refsum H, et al. Low circulating folate and vitamin B6 concentrations: risk factors for stroke, peripheral vascular disease, and coronary artery disease. European COMAC Group. Circulation 1998; 97: 437-43.
72. Rudzite V, Saliva A, Kalnins U, et al. Association between increased serum neopterin and homocysteine concentrations as well as pyridoxal phosphate deficiency in patients with coronary heart disease. Pteridines 2001; 12; 130-4.
73. Rudzite V, Jurika E, Schroecksnadel K, et al. Usefulness of neopterin, C-reactive protein, homocysteine, pyridoxal-5-phosphate, and phospholipid determination in coronary artery disease. Pteridines 2005; 16: 15-21.
74. Ulvik A, Midttun Ø, Pedersen ER, Nygård O, Ueland PM. Association of plasma B-6 vitamers with systemic markers of inflammation before and after pyridoxine treatment in patients with stable angina pectoris. Am J Clin Nutr 2012; 95: 1072-8.
75. Sakakeeny L, Roubenoff R, Obin M, et al. Plasma pyridoxal-5-phosphate is inversely associated with systemic markers of inflammation in a population of U. S. adults. J Nutr 2012; 142: 1280-5.
76. Christensen MH, Pedersen EK, Nordbø Y, et al. Vitamin B6 status and interferon-α-mediated immune activation in primary hyperparathyroidism. J Intern Med 2012; 272: 583-91.
77. Oxenkrug G, Tucker KL, Requintina P, Summergrad P. Neopterin, a marker of interferon-gamma-inducible inflammation, correlates with pyridoxal-5'-phosphate, waist circumference, HDLcholesterol, insulin resistance and mortality risk in adult Boston community dwellers of Puertorican origin. Am J Neuroprot Neuroregen 2011; 3: 48-52.
78. Murr C, Pilz S, Grammer T, et al. Vitamin D deficiency parallels inflammation and immune activation, the Ludwigshafen Risk and Cardiovascular Health (LURIC) study. Clin Chem Lab Med 2012; 20: 2205-12.
79. Werner ER, Bichler A, Daxenbichler G, et al. Determination of neopterin in serum and urine. Clin Chem 1987; 33: 62-6.
80. Mayersbach P, Augustin R, Schennach H, et al. Commercial enzyme-linked immunosorbent assay for neopterin detection in blood donations compared with RIA and HPLC. Clin Chem 1994; 40: 265-6.
81. Flavall EA, Crone EM, Moore GA, Gieseg SP. Dissociation of neopterin and 7,8-dihydroneopterin from plasma components before HPLC analysis. J Chromatogr B Analyt Technol Biomed Life Sci 2008; 863: 167-71.
82. Fuchs D, Milstien S, Krämer A, et al. Urinary neopterin concentrations vs total neopterins for clinical utility. Clin Chem 1989; 35: 2305-7.
83. Hara T, Yamakura F, Takikawa O, et al. Diazotization of kynurenine by acidified nitrite secreted from indoleamine 2,3-dioxygenase-expressing myeloid dendritic cells. J Immunol Methods 2008; 332: 162-9.
84. Mangge H, Schnedl WJ, Schroecksnadel S, Geisler S, Murr C, Fuchs D. Immune activation and inflammation in patients with cardiovascular disease are associated with elevated phenylalanine to tyrosine ratios. Pteridines 2013; 24: 51-5.
85. Murr C, Schroecksnadel K, Winklhofer-Roob BM, Mangge H, Böhm BO, Winkelmann BR, Maerz W, Fuchs D. Inverse association between serum concentrations of neopterin and antioxidants in patients with and without angiographic coronary artery disease. Atherosclerosis 2009; 202: 543-9.
86. Leblhuber F, Walli J, Artner-Dworzak E, et al. Hyperhomocysteinemia in dementia. J Neural Transm 2000; 107: 1469-74.
87. Widner B, Leblhuber F, Frick B, Laich A, Artner-Dworzak E, Fuchs D. Moderate hyperhomocysteinamia and immune activation in Parkinson's disease. J Neural Transm 2002; 109; 1445-52.
88. Turgan N, Habif S, Parildar Z, et al. Association between homocysteine and neopterin in healthy subjects measured by a simple HPLC-fluorometric method. Clin Biochem 2001; 34: 271-5.
89. Estelberger W, Weiss G, Petek W, Paletta B, Wachter H, Reibnegger G. Determination of renal clearance of neopterin by a pharmacokinetic approach. FEBS Lett 1993; 329: 13-6.
90. Pawlak K, Mysliwiec M, Pawlak D. Haemostatic system, biochemical profiles, kynurenines and the prevalence of cardiovascular disease in peritoneally dialyzed patients. Thromb Res 2010; 125: e40-5.
91. Fuchs D, Hausen A, Reibnegger G, Werner ER, Dittrich P, Wachter H: Neopterin levels in long term hemodialysis. Clin Nephrol 1988, 30: 220-4.
92. Koenig P, Nagl C, Neurauter G, Schennach H, Brandacher G, Fuchs. D. Enhanced degradation of tryptophan in patients on hemodialysis. Clin Nephrol 2010; 74: 465-70.
93. Schroecksnadel K, Grammer TB, Boehm BO, März W, Fuchs D. Total homocysteine in patients with angiographic coronary artery disease correlates with inflammation markers. Thromb Haemost 2010; 103: 926-35.
94. + lymphocytes: differences between young and elderly subjects. Exp Gerontol 2002; 37: 227-34.
95. + T-cells. Pteridines 2004; 15: 150-4.
96. Munn, DH, Shafizadeh E, Attwood JT, Bondarev I, Pashine A, Mellor AL. Inhibition of T-cell proliferation by macrophage tryptophan catabolism. J Exp Med 1999; 189: 1663-72.
97. Mellor AL, Munn DH. Tryptophan catabolism and T-cell tolerance: Immunosuppression by starvation? Immunol Today 1999; 20: 469-73.
98. Munn DH, Zhou M, Attwood JT, et al. Inhibition of T cell proliferation by macrophage tryptophan catabolism. Science 1998, 281: 1191-3.
99. Fallarino F, Grohmann U, Vacca C, et al. T cell apoptosis by tryptophan catabolism. Cell Death Differ 2002; 9: 1069-77.
100. Hill M, Tanguy-Royer S, Royer P, et al. IDO expands human CD4+CD25high regulatory T cells by promoting maturation of LPS-treated dendritic cells. Eur J Immunol 2007, 37: 3054-62.
101. Johnson BA, Baban B, Mellor AL. Targeting the immunoregulatory indoleamine 2,3 dioxygenase pathway in immunotherapy. Immunotherapy 2009, 1: 645-61.
102. Fuchs D, Zangerle R, Artner-Dworzak E, et al. Association between immune activation, changes of iron metabolism and anaemia in patients with HIV-infection. Eur J Haematol 1993; 50: 90-4.
103. Weiss G, Schroecksnadel K, Mattle V, Winkler C, Konwalinka G, Fuchs D. Possible role of cytokine-induced tryptophan degradation in anaemia of inflammation. Eur J Haematol 2004; 72: 130-4.
104. Denz H, Orth B, Weiss G, et al. Weight loss in patients with hematological neoplasias is associated with immune system stimulation. Clin Investig 1993; 71: 37-41.
105. Iwagaki H, Hizuta A, Tanaka N, Orita K. Decreased serum tryptophan in patients with cancer cachexia correlates with increased serum neopterin. Immunol Invest 1995; 24: 467-78.
106. Leng SX, Tian X, Matteini A, et al. IL-6-independent association of elevated serum neopterin levels with prevalent frailty in community-dwelling older adults. Age Ageing 2011; 40: 475-81.
107. Brandacher G, Schroecksnadel K, Winkler C, Margreiter R, Fuchs D. Antitumoral activity of interferon-DDinvolved in impaired immune function in cancer patients. Curr Drug Metabol 2006; 7: 599-612.
108. Schroecksnadel K, Winkler C, Duftner C, Wirleitner B, Schirmer M, Fuchs D. Tryptophan degradation increases with stage in patients with rheumatoid arthritis. Clin Rheumatol 2006; 25: 334-7.
109. Widner B, Sepp N, Kowald E, et al. Enhanced tryptophan degradation in systemic lupus erythematosus. Immunobiology 2000; 201: 621-30.
110. Vogelgesang SA, Heyes MP, West SG, et al. Quinolinic acid in patients with systemic lupus erythematosus and neuropsychiatric manifestations. J Rheumatol 1996; 23: 850-5.
111. Pertovaara M, Hasan T, Raitala A, et al. Indoleamine 2,3-dioxygenase activity is increased in patients with systemic lupus erythematosus and predicts disease activation in the sunny season. Clin Exp Immunol 2007; 150: 274-8.
112. Widner B, Leblhuber F, Walli J, Tilz GP, Demel U, Fuchs D. Tryptophan degradation and immune activation in Alzheimer's disease. J Neural Transm 2000; 107: 343-53.
113. Gulaj E, Pawlak K, Bien B, Pawlak D. Kynurenine and its metabolites in Alzheimer's disease patients. Adv Med Sci 2010; 55: 204-11.
114. Avanzas P, Arroyo-Espliguero R, Quiles J, Roy D, Kaski JC. Elevated serum neopterin predicts future adverse cardiac events in patients with chronic stable angina pectoris. Eur Heart J 2005; 26: 457-63.
115. Pertovaara M, Raitala A, Juonala M, et al. Indoleamine 2,3-dioxygenase enzyme activity correlates with risk factors for atherosclerosis: the Cardiovascular Risk in Young Finns Study. Clin Exp Immunol 2007; 148: 106-11.
116. Niinisalo P, Raitala A, Pertovaara M, et al. Indoleamine 2,3-dioxygenase activity associates with cardiovascular risk factors: the Health 2000 study. Scand J Clin Lab Invest 2008; 68: 767-70.
117. Elovainio M, Hurme M, Jokela M, et al. Moderating effect of indoleamine 2,3-dioxygenase (IDO) activation in the association between depressive symptoms and carotid atherosclerosis: evidence from the Young Finns study. J Affect Disord 2011; 133: 611-4.
118. Raitala A, Pertovaara M, Karjalainen J, Oja SS, Hurme M. Association of interferon-gamma +874(T/A) single nucleotide polymorphism with the rate of tryptophan catabolism in healthy individuals. Scand J Immunol 2005; 61: 387-90.
119. Oxenkrug G, Perianayagam M, Mikolich D, et al. Interferongamma (+874) T/A genotypes and risk of IFN-alpha-induced depression. J Neural Transm 2011; 118: 271-4.
120. Pawlak K, Domaniewski T, Mysliwiec M, Pawlak D. The kynurenines are associated with oxidative stress, inflammation and the prevalence of cardiovascular disease in patients with end-stage renal disease. Atherosclerosis 2009; 204: 309-14.
121. Sulo G, Vollset SE, Nygård O, et al. Neopterin and kynureninetryptophan ratio as predictors of coronary events in older adults, the Hordaland Health Study. Int J Cardiol 2013; 168: 1435-40.
122. Wissmann P, Geisler S, Leblhuber F, Fuchs D. Immune activation in patients with Alzheimer's disease is associated with higher serum phenylalanine concentrations. J Neurol Sci 2013; 329: 29-33.
123. Deschamps V, Barberger-Gateau P, Peuchant E, Orgogozo JM. Nutritional factors in cerebral aging and dementia: epidemiological arguments for a role of oxidative stress. Neuroepidemiology 2001; 20: 7-15.
124. Wu D, Meydani SN. Age-associated changes in immune and inflammatory responses: impact of vitamin E intervention. J Leukoc Biol 2008; 84: 900-14.
125. Jenny M, Klieber M, Zaknun D, et al. In vitro testing for antiinflammatory properties of compounds employing peripheral blood mononuclear cells freshly isolated from healthy donors. Inflamm Res 2011; 60: 127-35.
126. Zaknun D, Schroecksnadel S, Kurz K, Fuchs D. Potential role of antioxidant food supplements, preservatives and colorants in the pathogenesis of allergy and asthma. Int Arch Allergy Immunol 2012, 157: 113-24.
127. Schroecksnadel K, Winkler C, Wirleitner B, Schennach H, Fuchs D. Aspirin down-regulates tryptophan degradation in stimulated human peripheral blood mononuclear cells in vitro. Clin Exp Immunol 2005; 140: 41-5.
128. Schroecksnadel S, Jenny M, Kurz K, et al. LPS-induced NFkappaB expression in THP-1Blue cells correlates with neopterin production and activity of indoleamine 2,3-dioxygenase. Biochem Biophys Res Com 2010; 399: 642-6.
129. Schroecksnadel S, Sucher R, Kurz K, Fuchs, Brandacher G. Influence of immunosuppressive agents on tryptophan degradation and neopterin production in human peripheral blood mononuclear cells. Transplant Immunol 2011; 25: 119-23.
130. Tan PH, Sagoo P, Chan C, et al. Inhibition of NF-kappa B and oxidative pathways in human dendritic cells by antioxidative vitamins generates regulatory T cells. J Immunol 2005; 174: 7633-44.
131. Oxenkrug GF, Navrotskaya V, Voroboyva L, Summergrad P. Extension of life span of Drosophila melanogaster by the inhibitors of tryptophan-kynurenine metabolism. Fly (Austin) 2011; 5: 307-9.
132. Long SJ, Benton D. Effects of vitamin and mineral supplementation on stress, mild psychiatric symptoms, and mood in nonclinical samples: a meta-analysis. Psychosom Med. 2013; 75: 144-53.
133. German L, Kahana C, Rosenfeld V, et al. Depressive symptoms are associated with food insufficiency and nutritional deficiencies in poor community-dwelling elderly people. J Nutr Health Aging 2011; 15: 3-8.
134. Neurauter G, Wirleitner B, Laich A, Schennach H, Weiss G, Fuchs D. Atorvastatin suppresses interferon-D-induced neopterin formation and tryptophan degradation in human peripheral blood mononuclear cells and in monocytic cell lines. Clin Exp Immunol 2003; 131: 264-7.
135. Das DK, Mukherjee S, Ray D. Resveratrol and red wine, healthy heart and longevity. Heart Fail Rev 2010; 15: 467-77.
136. Thomazella MC, Góes MF, Andrade CR, et al. Effects of high adherence to Mediterranean or low-fat diets in medicated secondary prevention patients. Am J Cardiol 2011; 108: 1523-9.